Condition: Atopic Dermatitis (AD) · Sponsor: Jiangsu Genscend Biopharmaceutical Co., Ltd
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent® and CN commercial Dupixent® in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.
This description comes directly from the study's public registry record.
Sinian Li, Master · +086-15800767550 · lisinian@jxingbio.com
Tao Sun, Master · +086-15921575347 · suntao@jxingbio.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Soochow University | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07411755